Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 1/20 | 0.34 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.33 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 10/20 | 0.33 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.31 |
| ▸ | PDE5A | O76074 | 1/20 | 0.30 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.30 |
| ▸ | FEN1 | P39748 | 1/20 | 0.30 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23573957 | 1.00 | F10 (0.34) | F10ADRA1DADRA1AADRA1BUSP30 | |
| SCHEMBL23573959 | 1.00 | F10 (0.34) | F10ADRA1DADRA1AADRA1BUSP30 | |
| SCHEMBL23574034 | 0.87 | USP30 (0.41) | USP30UCHL1 | |
| SCHEMBL23574033 | 0.87 | USP30 (0.41) | USP30UCHL1 | |
| SCHEMBL30801869 | 0.82 | HTR2A (0.41) | F10ADRA1DADRA1AADRA1BPDE5A | |
| SCHEMBL23113745 | 0.73 | USP30 (0.44) | USP30UCHL1 | |
| SCHEMBL23113746 | 0.73 | USP30 (0.44) | USP30UCHL1 | |
| SCHEMBL23574098 | 0.73 | USP30 (0.44) | USP30UCHL1 | |
| SCHEMBL23573927 | 0.71 | UCHL1 (0.30) | UCHL1 | |
| SCHEMBL23573925 | 0.71 | UCHL1 (0.30) | UCHL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12049466-B2 | Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2024-07-30 | — | — | US | claimed |
| US-12049466-B2 | Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2024-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12049466-B2 | Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors | USP30, UCHL1, ADRM1 | F10 3637/4885ADRA1D 4101/4885ADRA1A 4250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.